Form D — Nasus Pharma Ltd
0001493152-26-008057 · filed Feb 25, 2026
Offering amounts describe securities offered; amounts sold are issuer-reported as of each filing. Amendments can repeat earlier amounts. We do not add these figures into a capital-raised total. Missing amounts are not zero. Data coverage and methodology · How to interpret the amounts.
Check this disclosure on SEC EDGAR · More Biotechnology filings
Offering
- Industry
- Biotechnology
- Exemptions
- 06b
- Reported offering amount
- $15,000,040
- Reported amount sold
- $15,000,040
- Minimum investment
- $0
- Investors
- —
- Sales commission
- —
- Finders' fees
- —
Issuer
- Name
- Nasus Pharma Ltd
- CIK
- 2029039
- Entity
- Corporation
- Jurisdiction
- ISRAEL
- Year incorporated
- —
- Address
- 34 YITZHAK SADEH ST
TEL AVIV, L3 6274711 - Phone
- +972.3.573.6632
Related persons
May not be accurate — issuers self-report this list and the SEC does not verify it. Cross-check the original SEC EDGAR filing if accuracy matters.
-
Dan Teleman · Executive OfficerTEL AVIV, L3 Find on LinkedIn ↗
-
Eyal Rubin · Executive OfficerTEL AVIV, L3 Find on LinkedIn ↗
-
Udi Gilboa · DirectorTEL AVIV, L3 Find on LinkedIn ↗
-
Dalia Megiddo · Executive OfficerTEL AVIV, L3 Find on LinkedIn ↗
-
Ronnie Hershman · DirectorTEL AVIV, L3 Find on LinkedIn ↗
-
David Silberman · DirectorTEL AVIV, L3 Find on LinkedIn ↗
-
Sharon Shacham · DirectorTEL AVIV, L3 Find on LinkedIn ↗
-
Isaac Israel · DirectorTEL AVIV, L3 Find on LinkedIn ↗
View the original filing on SEC EDGAR ↗